Adaptimmune Therapeutics Statistics
Total Valuation
MUN:473A has a market cap or net worth of EUR 6.25 million. The enterprise value is 25.29 million.
| Market Cap | 6.25M |
| Enterprise Value | 25.29M |
Important Dates
The next estimated earnings date is Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.53% |
| Shares Change (QoQ) | +2.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 244.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.11 |
| PB Ratio | -0.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.17 |
| EV / Sales | 0.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.15 |
Financial Position
The company has a current ratio of 1.52
| Current Ratio | 1.52 |
| Quick Ratio | 1.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -26.10 |
Financial Efficiency
Return on equity (ROE) is -1,341.10% and return on invested capital (ROIC) is -152.32%.
| Return on Equity (ROE) | -1,341.10% |
| Return on Assets (ROA) | -40.86% |
| Return on Invested Capital (ROIC) | -152.32% |
| Return on Capital Employed (ROCE) | -186.89% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 109,525 |
| Profits Per Employee | -285,666 |
| Employee Count | 506 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 20.28 |
Taxes
In the past 12 months, MUN:473A has paid 3.16 million in taxes.
| Income Tax | 3.16M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.65 |
Income Statement
In the last 12 months, MUN:473A had revenue of EUR 55.42 million and -144.55 million in losses. Loss per share was -0.56.
| Revenue | 55.42M |
| Gross Profit | -54.16M |
| Operating Income | -125.91M |
| Pretax Income | -141.39M |
| Net Income | -144.55M |
| EBITDA | -116.86M |
| EBIT | -125.91M |
| Loss Per Share | -0.56 |
Balance Sheet
The company has 22.19 million in cash and 41.45 million in debt, with a net cash position of -19.26 million.
| Cash & Cash Equivalents | 22.19M |
| Total Debt | 41.45M |
| Net Cash | -19.26M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -60.42M |
| Book Value Per Share | -0.23 |
| Working Capital | 22.65M |
Cash Flow
In the last 12 months, operating cash flow was -161.81 million and capital expenditures -1.40 million, giving a free cash flow of -163.20 million.
| Operating Cash Flow | -161.81M |
| Capital Expenditures | -1.40M |
| Free Cash Flow | -163.20M |
| FCF Per Share | n/a |
Margins
Gross margin is -97.73%, with operating and profit margins of -227.19% and -260.82%.
| Gross Margin | -97.73% |
| Operating Margin | -227.19% |
| Pretax Margin | -255.12% |
| Profit Margin | -260.82% |
| EBITDA Margin | -210.86% |
| EBIT Margin | -227.19% |
| FCF Margin | n/a |
Dividends & Yields
MUN:473A does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.53% |
| Shareholder Yield | -8.53% |
| Earnings Yield | -2,314.00% |
| FCF Yield | -2,612.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MUN:473A has an Altman Z-Score of -15.04. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.04 |
| Piotroski F-Score | n/a |